Articles related to PAIN MANAGEMENT

Exploring the multidimensional nature of fatigue in inflammatory arthritis patients uncovers the urgent need for a tailored, comprehensive approach in its management. Discover how an understanding of the complex interplay between physical, emotional, cognitive, and lifestyle factors can inform more effective patient care.

The I-WOTCH trial offers insightful findings on multimodal interventions for opioid-dependent chronic pain patients. Read on for a detailed examination of the trial’s significant impact on patient wellbeing and opioid cessation.

A Randomized, Controlled, Double-Blind Trial Analyzing Colchicine’s Role in Reducing Knee and Hip Replacement Incidences An exploratory analysis of the LoDoCo2 randomized trial has led to a promising correlation between low-dose colchicine treatment and a reduced incidence of knee and hip replacements.

FDA Cautions Against Hidden Drug Ingredients in Joint Pain Supplements In response to recent findings, the FDA warns of significant health risks associated with three specific dietary supplements marketed for joint pain and rheumatoid arthritis relief due to the discovery of unlisted active pharmaceutical ingredients.

Unveiling a new path in osteoarthritis pain management, the FDA’s Breakthrough Therapy designation for resiniferatoxin marks a promising development. The FDA has granted Breakthrough Therapy designation to resiniferatoxin for treating osteoarthritis knee pain. Extracted from a cactus-like plant, resiniferatoxin, a potent TRPV1 agonist, boasts similarities to capsaicin. Notably, its potency sets it apart. Resiniferatoxin is administered through intra-articular injection, promoting pain relief by temporarily disabling TRPV1-expressing nociceptors. This unique mechanism targets one of the most profound symptoms of osteoarthritis: pain. Its potential benefits are eagerly awaited by millions of patients struggling with this relentless disease. Stepping up to the challenge, Grünenthal, the company behind resiniferatoxin, is launching a global Phase 3 program. They aim to enroll more than 1,800 patients with knee osteoarthritis who haven’t found sufficient relief from existing non-surgical treatments. With a focus on improved pain and physical function scores according to the WOMAC osteoarthritis index, the program’s efficacy endpoints are set for up to 52 weeks. Turning the tide in osteoarthritis treatment, the Breakthrough Therapy Designation offers an expedited path for this non-opioid therapy option. As Grünenthal’s Chief Scientific Officer, Jan Adams, optimistically noted, it is hoped that this designation will speed up resiniferatoxin’s availability to patients.

Dive into the essence of AANA’s updated guidelines for obstetric anesthesia and analgesia as we spotlight its focus on health equity and safety in maternal care. Commencing with the unveiling of the revised practice guidelines for obstetric anesthesia and analgesia, the American Association of Nurse Anesthesiology (AANA) has emphasized enhancing patient care and safety. Interestingly, these updates also strive to tackle the critical issue of enduring health disparities in the United States. The AANA firmly believes in the power of certified registered nurse anesthetists (CRNAs) to help curb maternal mortality rates. The primary strategy focuses on mitigating racial and ethnic imbalances in pregnancy-related deaths. Beth Ann Clayton, DNP, CRNA, FAANA, FAAN, the key subject matter expert behind the revisions, underscores these inequalities as significant barriers to optimal maternal care. Using an evidence-based process, the AANA revised the guidelines, paying careful attention to current research. They’ve prioritized enhancing the readability of the content, updating the quality of references, and broadening their scope to encompass the most recent recommendations on obstetric analgesia and anesthesia care. The notable alterations include the broadening of analgesia and anesthesia considerations for labor and delivery. This expansion encompasses inhalation analgesia, neuraxial analgesia, general anesthesia, and an updated […]